Federal solicitation · NIMH26000869 · back to recent
Recurrent Glioblastomas
- Agency
- HEALTH AND HUMAN SERVICES, DEPARTMENT OF
- Status
- Closed
- Response deadline
- April 15, 2026
- Posted
- March 31, 2026
- Set-aside
- 8(a) sole source
- NAICS
- 541715
- Source
- View on SAM.gov
- Last checked
- 2026-05-01
Solicitation description
The goal of this clinical trial is to evaluate progression-free and overall survival in participants with recurrent glioblastoma receiving LMP744 compared to historic controls. We will also directly compare molecular and metabolic profiles of tissue, CSF, and plasma pre- and postexposure to LMP744 to determine pharmacologic responses to the drug in this patient population. We will also correlate the pre- and post-exposure molecular and metabolic profiles with clinical response and outcome, to determine which molecular and metabolic features are predictive of drug response. The latter information will be critical for the design of phase III clinical trials involving LMP744. Finally, we will evaluate the safety of LMP744 in patients with recurrent glioblastoma through continuous, objective monitoring. This is the first clinical trial to investigate the role of the novel indenoisoquinolone, CMYC/TOPOISOMERASE 1 inhibitor LMP744 in participants diagnosed with recurrent glioblastoma. Results from this study will provide objective assessment of the pharmacologic response to the drug and provide an initial assessment of efficacy when compared to historical controls. Our goal is to addresses the urgent need for effective therapies for patients with recurrent glioblastoma. Clinical trial monitoring of each enrolled patient (40 total) will be required for accutae assessment of safety for enrolled patients and future patients on study.
Vendor field in NAICS 541715 (12m)
Top 5 vendors by trailing-12m obligated dollars across this NAICS code, $2,640.7M total.
| LOCKHEED MARTIN CORPORATION | 19.4% |
| RAYTHEON COMPANY | 18.5% |
| THE MITRE CORPORATION | 13.4% |
| NORTHROP GRUMMAN SYSTEMS CORPORATION | 11.6% |
| INTUITIVE RESEARCH AND TECHNOLOGY CORPORATION | 9.6% |
Similar opportunities
Other open SAM.gov opportunities under the same NAICS, prioritizing the same buying agency.
| Title | Agency | Est. value | Basis |
|---|---|---|---|
| Evaluation and Conduct of Computational and Alternative... | HEALTH AND HUMAN... | $79.3M | same agency naics |
| 2026 NIAID DMID Omnibus Broad Agency Announcement | HEALTH AND HUMAN... | $23.9M | same agency naics |
| Analytical Services Center for Medications Development Program | HEALTH AND HUMAN... | $5.0M | same agency naics |
| NOI - Multi-dimensional sleep health and DNA methylation... | HEALTH AND HUMAN... | - | same agency naics |
| Office-Wide Innovative Solutions Opening for Resilient... | HEALTH AND HUMAN... | - | same agency naics |
| Quantitative Decision Reliability of AI-Accelerated... | HEALTH AND HUMAN... | - | same agency naics |
| Cytokine Profiling | HEALTH AND HUMAN... | - | same agency naics |
| Maximum Tolerated Dose (MTD) Evaluation of PIP4Kga | HEALTH AND HUMAN... | - | same agency naics |
Data this profile does not cover
- No likely incumbent surfaced; the solicitation number did not match any award record in the trailing window.